Xeris Biopharma (NASDAQ:XERS) Director Dawn Halkuff Sells 20,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Dawn Halkuff sold 20,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares of the company’s stock, valued at approximately $578,550. This trade represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

XERS stock traded up $0.03 during trading on Friday, reaching $6.18. 1,028,207 shares of the stock were exchanged, compared to its average volume of 1,829,779. The stock has a 50 day simple moving average of $6.08 and a 200-day simple moving average of $6.60. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $1.07 billion, a P/E ratio of 103.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a twelve month low of $4.30 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp boosted its holdings in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after acquiring an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd increased its position in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. 42.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on XERS. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.